Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions